"Kelonia's in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format."
"Personalized immunotherapy programs have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them."
Eli Lilly announced its acquisition of Kelonia Therapeutics for $7 billion, focusing on expanding its presence in Massachusetts. Kelonia, based in Dorchester, specializes in cell therapies for blood cancers, including a promising gene treatment for multiple myeloma. Shareholders will receive $3.25 billion upfront, with additional payments contingent on meeting specific milestones. Eli Lilly's executive highlighted the potential of Kelonia's platform to improve patient access to personalized immunotherapy, addressing existing barriers in manufacturing and safety. This acquisition follows several other significant purchases by Lilly in the Boston biotech sector.
Read at Boston.com
Unable to calculate read time
Collection
[
|
...
]